Australia Health

Nyrada (ASX:NYR) has received firm commitments to raise $12 million through a placement of approximately 19.4 million CHESS Depository Instruments.

Telix Pharmaceuticals (ASX:TLX) announced a strategic agreement to merge with ITM Isotope Technologies Munich SE in a deal valued at US$1.65 billion.

Memphasys (ASX:MEM) signed an exclusive three-year distribution agreement with specialist IVF supplier INVIDO LAB to commercialise its Felix System across the Czech Republic, Slovakia, and Kazakhstan.

Ramsay Santé presented its Connecting Care 2030, targeting annual revenue growth of approximately 3.0% through FY29.

Echo IQ (ASX:EIQ) has commenced work to resolve statistical analysis feedback from the US FDA.

Resonance Health (ASX:RHT) has signed a global strategic alliance and master services agreement with London-headquartered Image Analysis Group.

Biotechnology giant CSL (ASX:CSL) has acknowledged shareholder frustration after a tumultuous year marked by executive changes.

Paradigm Biopharmaceuticals (ASX:PAR) appointed Dr Daniel Furtner as chief medical officer, effective Sept. 16.

Mayne Pharma (ASX:MYX) secured exclusive five-year Australian rights to commercialise menopause gel Blissel.

Entropy Neurodynamics (ASX:ENP) reported positive Phase 2 trial results for its intravenous psilocin drug TRP-8803.

HealthCo Healthcare & Wellness REIT (ASX:HCW) and the Unlisted Healthcare Fund secured lender support to transfer operations across 10 hospitals to alternative operators.

Dimerix (ASX:DXB) was granted a composition of matter patent in Mexico for its clinical-stage asset, DMX-652.